Intercure Ltd

InterCure Ltd. engages in the business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies and Investments in Medical Cannabis Companies segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

InterCure reports record 2022 revenues, poised for global expansion

InterCure had a successful year in 2022, achieving record revenues and positioning itself for global expansion. The company's focus on the Israeli market, expansion of cultivation facilities, and addition of new product strains have been key drivers of growth. Despite challenges in patient procurement and regulatory complexities, InterCure is well-prepared to leverage opportunities in international markets.

InterCure reports record revenue and positive cash flow for 2022

InterCure's Q4 2022 earnings call highlighted a successful 2022, with record revenue and positive cash flow. The company's focus on leading the Israeli market, scaling up operations, and navigating market dynamics and regulatory differences positions it for continued growth. Despite industry challenges, InterCure is well-prepared to capitalize on opportunities presented by pricing trends and prescription reforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies in the Biomed Sector and Investments in the Medical Cannabis Sector segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.

The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders.

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure  Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies' branded products, produced from its cultivation and manufacturing facilities, initially in 8 licensed branded pharmacies across.

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken.

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. This prestigious event will bring together senior management teams from leading cannabis companies including InterCu.

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial Highlights and Milestones Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, a.

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to medical cannabis patient access to grow the market in 2024. InterCure stock is cheap at only about 1x sales, with catalysts for growth in 2024 and beyond.

InterCure: Bargain Israel Cannabis Play

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. Preliminary full year 2023 Financial Highlights and Milestones Annual revenue for 2023 is estimated at NIS 351 million, and revenue for the H2 2023 is estimated at NIS 140 million. EBITDA for 2023 is estimated at over NIS 50 Million, an.

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the “CannG” Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Canna.

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by removing cannabis from the 'narcotics act', is set to significantly ease the prescription process for medical cannabis, heralding profound implications for medical professionals, patients, and companies operating within th.

PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape

NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additional update regarding the status of its facility in Kibbutz Nir Oz (the “Southern Israel Site”).

InterCure Provides an Update Regarding Nir Oz Facility

NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm ”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing medical cannabis in Israel, by way of a share purchase of all of the issued and outstanding share capital of Leon Pharm (the “Transaction”).

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company's press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“Cannolam”), and the parties agreed on a binding arbitration process (the “Arbitration”), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders.

InterCure Wins Cannolam Arbitration Proceeding

NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees.

InterCure Provides an Update Regarding the Security Situation in Israel

Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

In mid-August, InterCure, one of the leaders in the global medical cannabis market, will publish financial results for the 2nd quarter of 2023. According to the Ministry of Health, the consumption of medical cannabis in Israel rose to 4.88 tons in June 2023 from 3.47 tons in June 2021. At the end of April 2023, a partnership was signed with Mike Tyson to distribute, cultivate and manufacture all TYSON 2.0 products in Israel, Australia, and certain European countries.

InterCure: Leader In Israel's Growing Medical Cannabis Market

NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), announced today that its board of directors (“Board”) has approved the voluntarily delisting of the Company's common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”).

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), reports today that, further to the Company's press release issued on February 1, 2023, where the Company had reported the termination of the merger agreement (the “Agreement”) with Cann Pharmaceutical Ltd. ("Better") due to fundamental disagreements between the parties thereto and that the closing conditions contained in the Agreement were not met, and further to the Company press release issued on February 14, 2023, where the Company had reported that it had filed  a lawsuit against Better to recover funds loaned to Better in the course of their dealings in connection with the Agreement, Better has filed a statement of defense and counterclaim against the Company, seeking, inter alia, a demand for the Company to consummate the transaction contemplated in the Agreement under its original terms or alternatively, an order for damages seemingly suffered by Better as a result of the termination of the Agreement.

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) is pleased to announce its financial and operating results for the first quarter ended March 31, 2023.

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company outside of North America announces that on April 24, 2023, it was informed that a lawsuit was filed against the Company in Tel Aviv-Jaffa District Court by minority shareholders of its subsidiary, Cannolam. The lawsuit was filed as part of a conflict between the shareholders and the Company, which is related to disagreements concerning the ongoing management of Cannolam.

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

NEW YORK, TORONTO, and HERZLIYA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading cannabis company outside of North America, announces that on April 23, 2023, it was informed that an application for approval of a class action in Israel was filed against twenty-six defendants, among them the leading cannabis groups in Israel, including the Company and three of its subsidiaries.

InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel

Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson's premium cannabis brand Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson's premium cannabis brand

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

Despite continued market challenges for the cannabis industry, InterCure's revenue continues to grow year-on-year and, more importantly, quarter-on-quarter to NIS 105.6 million in Q4 2022. InterCure's total comprehensive profit was NIS 43.7 million in 2022, up NIS 36.4 million from the previous year.

News for Intercure Ltd Stock (INCR)